Polycythemia Vera (PV) Clinical Trials and Treatments

Polycythemia Vera is one of the myeloproliferative neoplasms, a group of blood cancers in which bone marrow cells multiply uncontrollably. In PV, the overproduction of red blood cells increases blood volume and viscosity (thickness), which impairs blood flow and oxygen delivery despite elevated hemoglobin levels. The high blood viscosity also increases risk of blood clots (thrombosis) and bleeding complications.

The most common symptoms of Polycythemia Vera include Fatigue and weakness, Headaches and dizziness, Vision disturbances or blurred vision, Itching, especially after bathing, Burning sensations in the hands and feet, among others. About 44 to 57 per 100,000 people in the US, from 2 large health plans in 2008 to 2010 (Mehta et al., Leukemia and Lymphoma 2014); median age of diagnosis is 65 years. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Polycythemia Vera from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Research in Polycythemia Vera is expanding beyond traditional phlebotomy and aspirin toward targeted molecular therapies that address the underlying JAK2 mutations driving the disease. JAK2 inhibitors, HDAC inhibitors, and other innovative agents are being tested to reduce clot risk, lower disease burden, and improve quality of life for patients living with this condition.

Yes. As of October 21, 2026, 3 FDA-approved medicines have a current label that names Polycythemia Vera: Besremi (ropeginterferon alfa-2b-njft), first approved in 2021; Mimrylo (rusfertide), first approved in 2026; and Jakafi (ruxolitinib). Corticosteroids and immune globulins count once each.

Polycythemia Vera arises from acquired (somatic) genetic changes in the affected cells, commonly involving JAK2, rather than from an inherited variant. Nearly all patients carry an acquired JAK2 variant in blood cells; it is not inherited. About 44 to 57 per 100,000 people in the US, from 2 large health plans in 2008 to 2010 (Mehta et al., Leukemia and Lymphoma 2014); median age of diagnosis is 65 years.

For Polycythemia Vera the genetic testing that matters is usually of the tumor or affected blood cells rather than inherited DNA, looking for JAK2. Nearly all patients carry an acquired JAK2 variant in blood cells; it is not inherited.

Those results guide treatment choice and are often the entry requirement for targeted-therapy trials, so ask whether the biopsy was sent for molecular testing and request the report. The Genetic Testing section of this page lists laboratories in the NIH Genetic Testing Registry.

Eligibility for Polycythemia Vera clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Polycythemia Vera clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.